主页 > 生命科学 >
日本发现泰索帝可提高非小细胞肺癌患者存活
日本进行的三期研究结果表明，泰索帝药物辅之以顺铂，使患者的两年存活率比接受常规的长春地辛（vindesine）辅以顺铂的治疗增加一倍。
安万特表示，这项研究结果与去年8月发表的泰索帝合并顺铂比起常用的长春地辛结合顺铂的疗法更有利患者存活，并可提高生活品质和反应效果的另一研究结果是一致的。
screen.width-333)this.width=screen.width-333" width=440 height=277 title="Click to view full zlj0020409080001.gif (440 X 277)" border=0 align=absmiddle> J Clin Oncol. 2004 Jan 15; 22(2): 254-61.
Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group.
Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H.
Thoracic Oncology Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan; e-mail: kkubota@east.ncc.go.jp.
PURPOSE Few randomized trials have demonstrated survival benefit of combination chemotherapy involving new agents plus cisplatin compared with classic combination chemotherapy in advanced non-small-cell lung cancer (NSCLC). The primary aim of this study was to test whether docetaxel plus cisplatin (DC) improves survival compared with vindesine plus cisplatin (VdsC) in patients with previously untreated stage IV NSCLC. PATIENTS AND METHODS Eligible, stage IV, chemotherapy-naive patients (n = 311) were randomly assigned to receive docetaxel 60 mg/m(2) intravenously on day 1 plus cisplatin 80 mg/m(2) intravenously on day 1 of a 3- or 4-week cycle, or vindesine 3 mg/m(2) intravenously on days 1, 8, and 15 plus cisplatin 80 mg/m(2) intravenously on day 1 of a 4-week cycle. Cross-over administration of docetaxel and vindesine was prohibited for both treatment groups. Results Overall, 302 patients were eligible for evaluation. The DC arm demonstrated significant improvements compared with the VdsC arm in overall response rates (37% v 21%, respectively; P <.01) and median survival times (11.3 v 9.6 months, respectively; P =.014). Two-year survival rates were 24% for the DC arm compared with 12% for the VdsC arm. The physical domain of the Quality of Life for Cancer Patients Treated with Anticancer Drugs measure was significantly better in the DC arm than in the VdsC arm (P =.020). Toxicity was predominantly hematologic and was more severe in the VdsC arm. CONCLUSION As first-line treatment for stage IV NSCLC, DC resulted in greater clinical benefit in terms of response rate (with marked improvements in overall and 2-year survival rates) and quality of life than did treatment with VdsC.
screen.width-333)this.width=screen.width-333" width=440 height=374 title="Click to view full zlj0020409080003.gif (440 X 374)" border=0 align=absmiddle> [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-08-23 05:14
医学,生命科学网